<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04179630</url>
  </required_header>
  <id_info>
    <org_study_id>282-RI-103</org_study_id>
    <nct_id>NCT04179630</nct_id>
  </id_info>
  <brief_title>Study of Aldafermin (NGM282) in Participants With Impaired Renal Function</brief_title>
  <official_title>A Phase 1, Single-center, Open Label, Parallel Group Study to Evaluate the Pharmacokinetics, Safety &amp; Tolerability of a Single Dose of Aldafermin (NGM282) in Subjects With Impaired Renal Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NGM Biopharmaceuticals, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NGM Biopharmaceuticals, Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-center evaluation of Aldafermin (NGM282) in an open-label, single-dose and
      parallel group study in participants with Impaired Renal Function.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 8, 2019</start_date>
  <completion_date type="Actual">December 14, 2019</completion_date>
  <primary_completion_date type="Actual">December 4, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum observed plasma concentration (Cmax) of aldafermin (Day 1 through Day 4)</measure>
    <time_frame>12 Days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the concentration-time curve from time zero extrapolated to infinity (AUC 0-infinity) of aldafermin (Day 1 through Day 4)</measure>
    <time_frame>12 Days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Type and frequency of Adverse Events (Day 1 through Day 11)</measure>
    <time_frame>12 Days</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Impaired Renal Function</condition>
  <arm_group>
    <arm_group_label>Aldafermin (NGM282)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administered by subcutaneous injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Aldafermin (NGM282)</intervention_name>
    <description>Single 3 mg dose</description>
    <arm_group_label>Aldafermin (NGM282)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Current diagnosis of stable chronic kidney disease and eGFR, as assessed by the
             Modification of Diet in Renal Disease (MDRD) estimate:

               1. Mild renal impairment: eGFR 60-89 mL/min/1.73m²

               2. Moderate renal impairment: eGFR 30-59 mL/min/1.73m²

               3. Severe renal impairment: eGFR &lt; 30 mL/min/1.73m²

          -  Healthy control subjects with normal renal function will be matched (age ± 10 years;
             sex, race, BMI ± 15%) to their respective subject in the impaired renal function
             groups and have eGFR ≥90 mL/min/1.73m . Healthy control subjects should have no
             systemic chronic disease.

          -  Males and Females age 18-75

          -  Body mass index (BMI) 25-40 kg/m²

        Exclusion Criteria:

          -  Renal allograft recipients

          -  History of renal cell carcinoma or any history of metastatic disease involving the
             kidney

          -  End Stage Renal disease, requiring or not requiring dialysis

          -  Subject requiring or anticipated requirement of dialysis within 3 months of study
             entry

          -  Diagnosis of acute kidney injury/acute renal failure, or hospitalization for kidney
             related issue within 3 months of Screening

          -  Any renal disease or related condition actively being treated other than chronic
             kidney disease

          -  Any acute disease or condition being treated by medical therapy (prescription or over
             the counter) known to possibly impact renal function within 2 weeks of Screening

          -  History of treatment for a chronic condition with a medication that is known to have
             nephrotoxic potential, and after treatment, renal function/status has not been fully
             evaluated

          -  Uncontrolled hypertension

          -  Uncontrolled diabetes
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>NGM Study Director</last_name>
    <role>Study Director</role>
    <affiliation>NGM Biopharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>NGM Clinical Study Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>November 12, 2019</study_first_submitted>
  <study_first_submitted_qc>November 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 27, 2019</study_first_posted>
  <last_update_submitted>April 24, 2020</last_update_submitted>
  <last_update_submitted_qc>April 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

